EXACT Sciences Stock Price, News & Analysis (NASDAQ:EXAS)

$48.86 -0.28 (-0.57 %)
(As of 02/19/2018 08:48 AM ET)
Previous Close$49.14
Today's Range$48.24 - $49.43
52-Week Range$19.54 - $63.60
Volume1.23 million shs
Average Volume3.22 million shs
Market Capitalization$5.85 billion
P/E Ratio-42.12
Dividend YieldN/A
Beta0.58

About EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences logoExact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-284-5700

Debt

Debt-to-Equity Ratio0.01%
Current Ratio10.34%
Quick Ratio9.98%

Price-To-Earnings

Trailing P/E Ratio-42.1206896551724
Forward P/E Ratio-45.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$99.38 million
Price / Sales58.87
Cash FlowN/A
Price / CashN/A
Book Value$3.09 per share
Price / Book15.81

Profitability

Trailing EPS($1.16)
Net Income$-167,210,000.00
Net Margins-60.71%
Return on Equity-30.32%
Return on Assets-27.37%

Miscellaneous

Employees736
Outstanding Shares119,730,000

EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) posted its earnings results on Monday, October, 30th. The medical research company reported ($0.23) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.30) by $0.07. The medical research company had revenue of $72.60 million for the quarter, compared to analyst estimates of $65.03 million. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The company's revenue for the quarter was up 158.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.36) EPS. View EXACT Sciences' Earnings History.

When will EXACT Sciences make its next earnings announcement?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for EXACT Sciences.

Where is EXACT Sciences' stock going? Where will EXACT Sciences' stock price be in 2018?

14 analysts have issued 12 month price objectives for EXACT Sciences' stock. Their forecasts range from $28.00 to $67.00. On average, they anticipate EXACT Sciences' stock price to reach $53.23 in the next twelve months. View Analyst Ratings for EXACT Sciences.

What are Wall Street analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:

  • 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (1/19/2018)
  • 2. Cowen Inc analysts commented, "Colon cancer is the #2 cause of cancer death in the US, yet compliance with screening guidelines is low. Exact Sciences' Cologuard is less invasive than colonoscopy, more accurate than alternatives, FDA approved, in guidelines, and increasingly reimbursed. EXAS is targeting $4B of a ~$15B annual market opportunity. The 5-year revenue CAGR is forecast at ~50%. Initiate at Outperform with a $30 PT." (3/27/2017)

Are investors shorting EXACT Sciences?

EXACT Sciences saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 12,219,909 shares, an increase of 26.1% from the January 12th total of 9,688,211 shares. Based on an average daily trading volume, of 4,257,669 shares, the short-interest ratio is presently 2.9 days. Currently, 10.4% of the company's stock are short sold.

Who are some of EXACT Sciences' key competitors?

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:

  • Kevin T. Conroy, Chairman of the Board, President, Chief Executive Officer (Age 51)
  • Jeffrey Thomas Elliott, Chief Financial Officer (Age 39)
  • Maneesh K. Arora, Chief Operating Officer, Senior Vice President, Director (Age 48)
  • Graham Peter Lidgard Ph.D., Senior Vice President, Chief Scientific Officer (Age 68)
  • D. Scott Coward, Senior Vice President, General Counsel, Secretary (Age 52)
  • David A. Thompson, Lead Independent Director (Age 75)
  • Thomas D. Carey, Independent Director (Age 55)
  • James E. Doyle, Independent Director (Age 71)
  • John A. Fallon M.D., Independent Director (Age 69)
  • Daniel J. Levangie, Independent Director (Age 66)

Who owns EXACT Sciences stock?

EXACT Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.40%), OppenheimerFunds Inc. (2.44%), Gilder Gagnon Howe & Co. LLC (1.75%), Eagle Asset Management Inc. (1.50%), Fred Alger Management Inc. (1.48%) and William Blair Investment Management LLC (1.32%). Company insiders that own EXACT Sciences stock include D Scott Coward, David Thompson, Graham Peter Lidgard, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling, Maneesh Arora and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

Who sold EXACT Sciences stock? Who is selling EXACT Sciences stock?

EXACT Sciences' stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, ArrowMark Colorado Holdings LLC, Gilder Gagnon Howe & Co. LLC, Fred Alger Management Inc., Wasatch Advisors Inc., UBS Asset Management Americas Inc., Skylands Capital LLC and Allianz Asset Management GmbH. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Kevin T Conroy and Maneesh Arora. View Insider Buying and Selling for EXACT Sciences.

Who bought EXACT Sciences stock? Who is buying EXACT Sciences stock?

EXACT Sciences' stock was bought by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Victory Capital Management Inc., Emerald Advisers Inc. PA, Jennison Associates LLC, Deutsche Bank AG, BlackRock Inc., Lombard Odier Asset Management USA Corp and California Public Employees Retirement System. Company insiders that have bought EXACT Sciences stock in the last two years include David Thompson, James Edward Doyle, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

How do I buy EXACT Sciences stock?

Shares of EXACT Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXACT Sciences stock can currently be purchased for approximately $48.86.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $5.85 billion and generates $99.38 million in revenue each year. The medical research company earns $-167,210,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. EXACT Sciences employs 736 workers across the globe.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.


MarketBeat Community Rating for EXACT Sciences (EXAS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  571 (Vote Outperform)
Underperform Votes:  323 (Vote Underperform)
Total Votes:  894
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

EXACT Sciences (NASDAQ:EXAS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.642.642.622.77
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $53.23$51.85$50.77$40.77
Price Target Upside: 20.65% upside8.74% upside15.90% downside9.21% upside

EXACT Sciences (NASDAQ:EXAS) Consensus Price Target History

Price Target History for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ:EXAS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018Leerink SwannSet Price TargetBuy$67.00MediumView Rating Details
1/29/2018Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$17.77 -> $51.00LowView Rating Details
1/17/2018BenchmarkSet Price TargetBuy$65.00MediumView Rating Details
1/10/2018William BlairReiterated RatingBuyHighView Rating Details
1/8/2018Bank of AmericaSet Price TargetBuy$67.00HighView Rating Details
11/13/2017Robert W. BairdDowngradeOutperform -> Neutral$56.00N/AView Rating Details
11/1/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
10/31/2017Canaccord GenuityUpgradeBuy$60.00N/AView Rating Details
10/31/2017Craig HallumBoost Price TargetBuy$46.00 -> $61.00N/AView Rating Details
10/31/2017Jefferies GroupBoost Price TargetBuy$60.00N/AView Rating Details
7/26/2017Roth CapitalBoost Price TargetBuy$40.00 -> $46.00HighView Rating Details
7/26/2017Lake Street CapitalBoost Price TargetHold -> Hold$30.00 -> $41.00MediumView Rating Details
6/7/2017StephensSet Price TargetHold$28.00MediumView Rating Details
5/31/2017CowenReiterated RatingOutperform$45.00HighView Rating Details
7/27/2016MizuhoBoost Price TargetNeutral$10.00 -> $15.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

EXACT Sciences (NASDAQ:EXAS) Earnings History and Estimates Chart

Earnings by Quarter for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ EXAS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018($0.29)N/AView Earnings Details
10/30/2017Q3 2017($0.30)($0.23)$65.03 million$72.60 millionViewN/AView Earnings Details
7/25/2017Q2 2017($0.37)($0.27)$47.73 million$57.65 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.32)$37.38 million$48.36 millionViewN/AView Earnings Details
2/21/2017Q416($0.39)($0.34)$32.53 million$35.24 millionViewListenView Earnings Details
10/26/2016Q316($0.43)($0.36)$25.24 million$28.10 millionViewListenView Earnings Details
7/26/2016Q216($0.55)($0.46)$18.54 million$21.20 millionViewListenView Earnings Details
5/3/2016Q116($0.52)($0.49)$15.17 million$14.80 millionViewN/AView Earnings Details
2/24/2016Q415($0.47)($0.41)$14.96 million$14.40 millionViewListenView Earnings Details
10/29/2015Q315($0.44)($0.45)$12.56 million$12.60 millionViewListenView Earnings Details
7/20/2015Q215($0.45)($0.44)$7.96 million$8.10 millionViewListenView Earnings Details
5/4/2015Q115($0.41)($0.40)$4.11 million$4.30 millionViewN/AView Earnings Details
2/24/2015Q414($0.39)($0.38)$19.90 million$1.15 millionViewN/AView Earnings Details
10/27/2014Q314($0.34)($0.39)$0.13 millionViewListenView Earnings Details
7/22/2014Q214($0.25)($0.24)$0.03 millionViewN/AView Earnings Details
5/1/2014Q114($0.19)($0.23)$0.40 million$0.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.19)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
10/29/2013Q313($0.18)($0.16)$1.02 million$1.00 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.18)($0.19)$1.02 million$1.00 millionViewN/AView Earnings Details
5/1/2013Q1 2013($0.20)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.18)($0.22)$1.04 million$1.00 millionViewN/AView Earnings Details
10/30/2012Q312($0.21)($0.21)$1.03 million$1.04 millionViewN/AView Earnings Details
7/25/2012($0.20)($0.26)ViewN/AView Earnings Details
5/1/2012($0.18)($0.19)ViewN/AView Earnings Details
2/23/2012($0.17)($0.18)ViewN/AView Earnings Details
11/3/2011($0.15)($0.15)ViewN/AView Earnings Details
8/2/2011($0.10)($0.13)ViewN/AView Earnings Details
5/3/2011($0.09)($0.08)ViewN/AView Earnings Details
2/15/2011($0.08)($0.08)ViewN/AView Earnings Details
10/27/2010Q3 2010($0.08)($0.08)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.07)($0.06)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.05)($0.06)ViewN/AView Earnings Details
2/16/2010Q4 2009($0.06)($0.05)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.03)ViewN/AView Earnings Details
8/12/2009Q2 2009($0.08)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.13)ViewN/AView Earnings Details
3/30/2009Q4 2008($0.08)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.09)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.08)ViewN/AView Earnings Details
5/5/2008Q1 2008($0.09)ViewN/AView Earnings Details
2/4/2008Q4 2007($0.14)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

EXACT Sciences (NASDAQ:EXAS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.33)($0.24)($0.27)
Q2 20184($0.33)($0.18)($0.24)
Q3 20184($0.32)($0.10)($0.20)
Q4 20184($0.31)($0.03)($0.15)
Q1 20191($0.14)($0.14)($0.14)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for EXACT Sciences (NASDAQ:EXAS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

EXACT Sciences (NASDAQ EXAS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 84.88%
Insider Trades by Quarter for EXACT Sciences (NASDAQ:EXAS)
Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ EXAS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2018Kevin T ConroyInsiderSell101,488$45.72$4,640,031.36931,540View SEC Filing  
1/23/2018Kevin T ConroyInsiderSell110,439$50.49$5,576,065.11940,491View SEC Filing  
1/12/2018Kevin T ConroyInsiderSell125,402$52.79$6,619,971.58955,454View SEC Filing  
1/3/2018D Scott CowardSVPSell1,665$52.54$87,479.1037,558View SEC Filing  
12/22/2017Kevin T ConroyInsiderSell123,512$52.58$6,494,260.96953,564View SEC Filing  
12/6/2017Kevin T ConroyInsiderSell121,849$53.45$6,512,829.05951,901View SEC Filing  
12/1/2017Graham Peter LidgardInsiderSell45,770$58.27$2,667,017.90237,820View SEC Filing  
11/21/2017Kevin T ConroyInsiderSell134,057$59.50$7,976,391.50View SEC Filing  
11/9/2017Kevin T ConroyCEOSell137,805$59.14$8,149,787.70967,867View SEC Filing  
11/1/2017Graham Peter LidgardInsiderSell45,775$53.60$2,453,540.00272,819View SEC Filing  
10/2/2017D Scott CowardSVPSell29,115$47.16$1,373,063.4064,991View SEC Filing  
10/2/2017Graham Peter LidgardInsiderSell81,025$47.16$3,821,139.00366,519View SEC Filing  
9/5/2017Graham Peter LidgardInsiderSell75,683$40.81$3,088,623.23308,377View SEC Filing  
9/1/2017Graham Peter LidgardInsiderSell45,775$41.49$1,899,204.75288,952View SEC Filing  
8/17/2017Thomas D CareyDirectorBuy2,500$37.71$94,275.0060,858View SEC Filing  
7/31/2017Jeffrey Thomas ElliottCFOSell5,846$39.41$230,390.8619,861View SEC Filing  
7/3/2017D Scott CowardSVPSell1,987$35.21$69,962.2757,603View SEC Filing  
4/3/2017D Scott CowardSVPSell1,543$23.74$36,630.8255,478View SEC Filing  
3/13/2017D Scott CowardSVPSell1,983$21.16$41,960.2850,790View SEC Filing  
3/13/2017Kevin T ConroyInsiderSell12,059$21.16$255,168.44817,239View SEC Filing  
3/13/2017Maneesh AroraCOOSell5,574$21.16$117,945.84556,339View SEC Filing  
2/27/2017D Scott CowardSVPSell7,046$21.48$151,348.0853,794View SEC Filing  
2/27/2017Graham Peter LidgardInsiderSell8,668$21.51$186,448.68314,527View SEC Filing  
2/27/2017Maneesh AroraCOOSell11,114$21.50$238,951.00535,940View SEC Filing  
1/3/2017D Scott CowardSVPSell1,535$13.61$20,891.3529,242View SEC Filing  
12/14/2016David ThompsonDirectorBuy10,000$13.84$138,400.00136,379View SEC Filing  
11/15/2016Kevin T ConroyInsiderSell600,000$17.46$10,476,000.001,340,057View SEC Filing  
11/15/2016Maneesh AroraCOOSell562,932$17.46$9,828,792.721,094,309View SEC Filing  
9/1/2016Lionel SterlingDirectorBuy5,000$18.10$90,500.00121,247View SEC Filing  
8/3/2016Katherine S ZanottiDirectorBuy3,380$17.93$60,603.40105,927View SEC Filing  
7/26/2016Graham Peter LidgardInsiderSell7,383$14.82$109,416.06227,592View SEC Filing  
7/26/2016Maneesh AroraCOOSell7,359$14.82$109,060.38538,736View SEC Filing  
4/1/2016D Scott CowardSVPSell1,685$6.62$11,154.7021,014View SEC Filing  
3/10/2016D Scott CowardSVPSell2,175$6.05$13,158.7518,501View SEC Filing  
3/10/2016Graham Peter LidgardInsiderSell3,041$6.05$18,398.05228,170View SEC Filing  
3/10/2016Maneesh AroraCOOSell4,042$6.05$24,454.10273,210View SEC Filing  
3/8/2016James Edward DoyleDirectorBuy5,000$6.43$32,150.0021,459View SEC Filing  
3/3/2016Katherine S NapierDirectorBuy3,775$5.38$20,309.5091,000View SEC Filing  
3/1/2016Kevin T ConroyCEOBuy50,000$5.00$250,000.00687,907View SEC Filing  
2/26/2016Kevin T ConroyCEOSell6,895$5.81$40,059.95637,907View SEC Filing  
2/25/2016Graham Peter LidgardInsiderSell2,997$5.52$16,543.44222,742View SEC Filing  
2/25/2016Maneesh AroraCOOSell4,099$5.52$22,626.48266,034View SEC Filing  
2/23/2016Graham Peter LidgardInsiderSell2,411$6.39$15,406.29216,903View SEC Filing  
2/23/2016Kevin T ConroyCEOSell6,866$6.39$43,873.74632,168View SEC Filing  
2/23/2016Maneesh AroraCOOSell2,556$6.39$16,332.84257,590View SEC Filing  
1/11/2016David ThompsonDirectorBuy15,000$6.99$104,850.00110,213View SEC Filing  
2/26/2015Graham Peter LidgardDirectorSell3,938$23.44$92,306.72View SEC Filing  
2/26/2015Kevin T ConroyCEOSell8,425$23.44$197,482.00View SEC Filing  
2/26/2015Maneesh AroraCOOSell3,895$23.44$91,298.80View SEC Filing  
2/24/2015Graham Peter LidgardDirectorSell4,037$22.90$92,447.30View SEC Filing  
2/24/2015Kevin T ConroyCEOSell9,798$22.90$224,374.20View SEC Filing  
2/24/2015Maneesh AroraCOOSell2,995$22.90$68,585.50View SEC Filing  
1/2/2015Graham Peter LidgardInsiderSell3,363$26.72$89,859.36View SEC Filing  
1/2/2015Kevin T ConroyCEOSell9,484$26.72$253,412.48View SEC Filing  
1/2/2015Maneesh AroraCOOSell2,495$26.72$66,666.40View SEC Filing  
10/29/2014Graham Peter LidgardInsiderSell8,015$24.68$197,810.20View SEC Filing  
7/25/2014Graham Peter LidgardVPSell11,081$15.99$177,185.19View SEC Filing  
7/25/2014Kevin T ConroyCEOSell11,336$15.99$181,262.64View SEC Filing  
7/25/2014Maneesh AroraCOOSell9,291$15.99$148,563.09View SEC Filing  
5/5/2014William MeganSVPBuy10,000$11.79$117,900.0012,522View SEC Filing  
2/24/2014Graham Peter LidgardVPSell3,160$14.07$44,461.20106,214View SEC Filing  
2/24/2014Kevin ConroyCEOSell8,708$14.07$122,521.56134,374View SEC Filing  
2/24/2014Maneesh AroraCOOSell2,662$14.07$37,454.3465,855View SEC Filing  
1/2/2014Graham Peter LidgardVPSell10,288$11.96$123,044.48102,149View SEC Filing  
1/2/2014Kevin ConroyCEOSell26,379$11.96$315,492.84123,707View SEC Filing  
1/2/2014Maneesh AroraCOOSell8,627$11.96$103,178.9261,292View SEC Filing  
10/28/2013Graham Peter LidgardVPSell7,430$11.07$82,250.10View SEC Filing  
9/20/2013Sally CrawfordDirectorSell25,000$12.19$304,750.00203,866View SEC Filing  
11/2/2012Kevin T ConroyCEOBuy2,000$9.13$18,260.00View SEC Filing  
11/2/2012Maneesh AroraCFOBuy1,000$9.04$9,040.00View SEC Filing  
11/1/2012Lionel SterlingDirectorBuy5,500$9.08$49,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

EXACT Sciences (NASDAQ EXAS) News Headlines

Source:
DateHeadline
EXACT Sciences (EXAS) to Release Earnings on ThursdayEXACT Sciences (EXAS) to Release Earnings on Thursday
www.americanbankingnews.com - February 15 at 1:08 AM
EXACT Sciences Co. (EXAS) Insider Kevin T. Conroy Sells 101,488 SharesEXACT Sciences Co. (EXAS) Insider Kevin T. Conroy Sells 101,488 Shares
www.americanbankingnews.com - February 13 at 6:10 PM
Zacks: Analysts Expect EXACT Sciences Co. (EXAS) Will Post Quarterly Sales of $87.30 MillionZacks: Analysts Expect EXACT Sciences Co. (EXAS) Will Post Quarterly Sales of $87.30 Million
www.americanbankingnews.com - February 11 at 6:30 AM
Leerink Swann Analysts Give EXACT Sciences (EXAS) a $67.00 Price TargetLeerink Swann Analysts Give EXACT Sciences (EXAS) a $67.00 Price Target
www.americanbankingnews.com - February 10 at 5:48 PM
EXACT Sciences Co. (EXAS) Short Interest Up 26.1% in JanuaryEXACT Sciences Co. (EXAS) Short Interest Up 26.1% in January
www.americanbankingnews.com - February 9 at 5:26 PM
FY2017 EPS Estimates for EXACT Sciences Co. (EXAS) Lifted by Leerink SwannFY2017 EPS Estimates for EXACT Sciences Co. (EXAS) Lifted by Leerink Swann
www.americanbankingnews.com - February 9 at 7:40 AM
 Brokerages Expect EXACT Sciences Co. (EXAS) to Post -$0.29 EPS Brokerages Expect EXACT Sciences Co. (EXAS) to Post -$0.29 EPS
www.americanbankingnews.com - February 9 at 5:08 AM
EXACT Sciences Co. Expected to Earn FY2019 Earnings of $0.29 Per Share (EXAS)EXACT Sciences Co. Expected to Earn FY2019 Earnings of $0.29 Per Share (EXAS)
www.americanbankingnews.com - February 8 at 4:58 PM
Exact Sciences schedules fourth-quarter, full-year 2017 earnings callExact Sciences schedules fourth-quarter, full-year 2017 earnings call
finance.yahoo.com - February 8 at 8:10 AM
Could Exact Sciences Corporation Be a Millionaire-Maker Stock?Could Exact Sciences Corporation Be a Millionaire-Maker Stock?
www.fool.com - February 7 at 7:43 AM
EXACT Sciences Co. (EXAS) Given Average Recommendation of "Buy" by BrokeragesEXACT Sciences Co. (EXAS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 3 at 5:34 PM
Exact Sciences to participate in Leerink Partners 7th Annual Global Healthcare ConferenceExact Sciences to participate in Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 1 at 9:31 AM
EXACT Sciences (EXAS) Now Covered by Goldman Sachs GroupEXACT Sciences (EXAS) Now Covered by Goldman Sachs Group
www.americanbankingnews.com - January 29 at 6:02 PM
EXACT Sciences Co. (EXAS) Short Interest UpdateEXACT Sciences Co. (EXAS) Short Interest Update
www.americanbankingnews.com - January 27 at 3:16 AM
Exact Sciences Corp (EXAS) President and CEO Kevin T Conroy Sold $5.6 million of SharesExact Sciences Corp (EXAS) President and CEO Kevin T Conroy Sold $5.6 million of Shares
finance.yahoo.com - January 26 at 9:07 AM
Kevin T. Conroy Sells 110,439 Shares of EXACT Sciences Co. (EXAS) StockKevin T. Conroy Sells 110,439 Shares of EXACT Sciences Co. (EXAS) Stock
www.americanbankingnews.com - January 25 at 9:12 PM
$83.38 Million in Sales Expected for EXACT Sciences Co. (EXAS) This Quarter$83.38 Million in Sales Expected for EXACT Sciences Co. (EXAS) This Quarter
www.americanbankingnews.com - January 25 at 4:38 AM
Who Are The Top Investors In Exact Sciences Corporation (NASDAQ:EXAS)?Who Are The Top Investors In Exact Sciences Corporation (NASDAQ:EXAS)?
finance.yahoo.com - January 21 at 4:44 PM
EXACT Sciences (EXAS) Rating Lowered to Hold at Zacks Investment ResearchEXACT Sciences (EXAS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 19 at 11:32 PM
The Market In 5 Minutes: Jobless Claims Fall, Walmart Upgrade, CryptocurrenciesThe Market In 5 Minutes: Jobless Claims Fall, Walmart Upgrade, Cryptocurrencies
finance.yahoo.com - January 18 at 4:41 PM
Flawed Taiwan Study Causes Drop in Shares of Exact Sciences (EXAS)'Flawed' Taiwan Study Causes Drop in Shares of Exact Sciences (EXAS)
www.streetinsider.com - January 18 at 10:36 AM
The Sell-Side Weighs In: Was The Exact Sciences Sell-Off Overdone?The Sell-Side Weighs In: Was The Exact Sciences Sell-Off Overdone?
finance.yahoo.com - January 18 at 10:36 AM
Kevin T. Conroy Sells 125,402 Shares of EXACT Sciences Co. (EXAS) StockKevin T. Conroy Sells 125,402 Shares of EXACT Sciences Co. (EXAS) Stock
www.americanbankingnews.com - January 17 at 6:28 PM
EXACT Sciences (EXAS) PT Set at $65.00 by BenchmarkEXACT Sciences (EXAS) PT Set at $65.00 by Benchmark
www.americanbankingnews.com - January 17 at 6:10 PM
Why Exact Sciences Will Plunge Even FurtherWhy Exact Sciences Will Plunge Even Further
finance.yahoo.com - January 17 at 5:17 PM
Exact Sciences: Wait, Its Not That Bad!Exact Sciences: Wait, It's Not That Bad!
finance.yahoo.com - January 17 at 5:17 PM
Today’s Research Reports on Stocks to Watch: Concert Pharmaceuticals and Exact Sciences CorporationToday’s Research Reports on Stocks to Watch: Concert Pharmaceuticals and Exact Sciences Corporation
finance.yahoo.com - January 15 at 9:38 AM
Exact Sciences Announces Offering of $500 Million Convertible Senior Notes Due 2025Exact Sciences Announces Offering of $500 Million Convertible Senior Notes Due 2025
finance.yahoo.com - January 11 at 5:14 PM
EXACT Sciences (EXAS) Rating Reiterated by William BlairEXACT Sciences (EXAS) Rating Reiterated by William Blair
www.americanbankingnews.com - January 10 at 11:32 AM
3 Slides That Paint a Great Picture for Exact Sciences' Future3 Slides That Paint a Great Picture for Exact Sciences' Future
finance.yahoo.com - January 10 at 9:47 AM
EXACT Sciences Co. (EXAS) Receives Average Rating of "Buy" from AnalystsEXACT Sciences Co. (EXAS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 7:44 PM
EXACT Sciences: Wait For a Better Buying OpportunityEXACT Sciences: Wait For a Better Buying Opportunity
finance.yahoo.com - January 9 at 5:12 PM
Cologuard maker Exact Sciences to develop lung and liver ...Cologuard maker Exact Sciences to develop lung and liver ...
finance.yahoo.com - January 9 at 9:43 AM
Biotech Exact Sciences 13% Plunge Could Get SteeperBiotech Exact Sciences' 13% Plunge Could Get Steeper
finance.yahoo.com - January 9 at 9:43 AM
Exact Sciences: Cramers Top TakeawaysExact Sciences: Cramer's Top Takeaways
finance.yahoo.com - January 9 at 9:43 AM
Exact Sciences (EXAS) Reports Prelim. Q4 & FY17 Revenues Above ConsensusExact Sciences (EXAS) Reports Prelim. Q4 & FY17 Revenues Above Consensus
www.streetinsider.com - January 8 at 5:14 PM
Why Exact Sciences Is Tumbling TodayWhy Exact Sciences Is Tumbling Today
finance.yahoo.com - January 8 at 5:14 PM
Is Exact Sciences Corporation (NASDAQ:EXAS) As Financially Strong As Its Balance Sheet Indicates?Is Exact Sciences Corporation (NASDAQ:EXAS) As Financially Strong As Its Balance Sheet Indicates?
finance.yahoo.com - January 8 at 9:40 AM
EXACT Sciences Co. (EXAS) Expected to Post Earnings of -$0.29 Per ShareEXACT Sciences Co. (EXAS) Expected to Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - January 6 at 3:06 AM
Life Sciences Pioneer Stanley Lapidus Joins Atlas Genetics Board of DirectorsLife Sciences Pioneer Stanley Lapidus Joins Atlas Genetics Board of Directors
www.businesswire.com - January 5 at 4:54 PM
Insider Selling: EXACT Sciences Co. (EXAS) SVP Sells 1,665 Shares of StockInsider Selling: EXACT Sciences Co. (EXAS) SVP Sells 1,665 Shares of Stock
www.americanbankingnews.com - January 4 at 8:26 PM
Is This Why Exact Sciences Fell 11.7% in December?Is This Why Exact Sciences Fell 11.7% in December?
finance.yahoo.com - January 4 at 5:09 PM
Protagonist Therapeutics (PTGX) vs. EXACT Sciences (EXAS) Head to Head SurveyProtagonist Therapeutics (PTGX) vs. EXACT Sciences (EXAS) Head to Head Survey
www.americanbankingnews.com - January 2 at 5:12 PM
EXACT Sciences (EXAS) "Buy" Rating Reaffirmed at William BlairEXACT Sciences' (EXAS) "Buy" Rating Reaffirmed at William Blair
www.americanbankingnews.com - January 2 at 10:20 AM
EXACT Sciences (EXAS) Downgraded by Robert W. Baird to NeutralEXACT Sciences (EXAS) Downgraded by Robert W. Baird to Neutral
www.americanbankingnews.com - December 31 at 4:22 PM
Beyond southeast Wisconsin: Titletown, Lands End, Exact Sciences among top state news stories of 2017—Year in ... - Milwaukee Business JournalBeyond southeast Wisconsin: Titletown, Lands' End, Exact Sciences among top state news stories of 2017—Year in ... - Milwaukee Business Journal
www.bizjournals.com - December 28 at 7:45 AM
EXACT Sciences Co. (EXAS) Insider Sells $6,494,260.96 in StockEXACT Sciences Co. (EXAS) Insider Sells $6,494,260.96 in Stock
www.americanbankingnews.com - December 26 at 5:36 PM
EXACT Sciences Co. (EXAS) Expected to Post Quarterly Sales of $76.55 MillionEXACT Sciences Co. (EXAS) Expected to Post Quarterly Sales of $76.55 Million
www.americanbankingnews.com - December 22 at 9:08 AM
EXACT Sciences (EXAS) Rating Increased to Buy at BidaskClubEXACT Sciences (EXAS) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - December 22 at 1:00 AM
Exact Sciences to participate in J.P. Morgan Healthcare ConferenceExact Sciences to participate in J.P. Morgan Healthcare Conference
finance.yahoo.com - December 20 at 9:45 AM

SEC Filings

EXACT Sciences (NASDAQ:EXAS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

EXACT Sciences (NASDAQ:EXAS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

EXACT Sciences (NASDAQ EXAS) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.